Biogen to pay $1.25 billion for patents to MS drugs; Supreme Court to hear Novartis case over Zarxio delay; Merck KGaA inks big-data deal
CVS to sell generic EpiPen; FDA finalizes biosimilar naming rules; Pfizer wants to make a deal
The firm is sharing space in the City of Brotherly Love with healthcare media shop CMI.
There are dozens of players, including leaders like IBM Watson Health and Verily as well as smaller concerns, lining up to sell pharma access to some sort of data solution.
Trump says pharma is "getting away with murder"; Senate majority votes to repeal ACA; IBM Watson Health and FDA to study blockchain technology
Merck said the FDA accepted its submission of a Keytruda/chemotherapy combo drug and granted it Priority Review.
J&J's CEO may be right. Customers of all kinds are demanding change.
The FDA accepts Keytruda combo for review; Valeant offloads Dendreon and skincare brands; pharmacies feeling the squeeze from Express Scripts
DeViteri started in the newly created role this month.
The American College of Physicians said the costs of some new diabetes drugs do not always mean added benefits for patients.
Physicians do not like EHRs. That much is clear. But the vast majority have to use electronic record systems on a daily basis. What can pharma do to better give doctors what they want?
The questions being asked about how drugs are priced are weighing heavily on pharma leaders, and they know the issue is not going away.
Illumina and IBM enter DNA sequencing partnership; J&J to outline price increases in new report; Egalet's opioid Arymo ER gets FDA approval
The top-selling heart drug is Merck's Zetia, which is expected to bring in about $1.68 billion in sales in 2016.
Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.
The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?
The new agency will focus on marketing goods and services to people 50 years of age and older.
She says her experience in consumer brands helps her push healthcare clients to be more creative.
Takeda to acquire Ariad for $4.6 billion, Merck pairs with Incyte for Keytruda combo drug collaboration; Sanofi announces autoimmune research deal
Otsuka, Astellas, Takeda, and Daiichi Sankyo share a degree of adventurousness and forward-mindedness in the digital realm.
When his mother suffered from ovarian cancer a decade ago, Robert Herjavec found himself frustrated by the quality of care she received.
Judge halts Praluent sales; clinical-trial data for Diclegis in question; cancer drugs to make up larger portion of total drug spending
The agency has faced questions about how it regulates off-label communications.
Orexigen launches new campaign for weight-loss drug Contrave; Arena sells Belviq to Eisai; Alexion reportedly pushed for 'pull-in' sales
The merger of Quintiles and IMS Health closed in October.
Sanofi, Regeneron denied bid to overturn Amgen win in patent case; Abbott to close St. Jude deal; Gilead hires SVP of hematology and oncology
With 2016 in the rearview, here are four stats detailing how the FDA fared last year in enforcing regulations and approving new drugs.
Facebook and Instagram are the primary location for brands to engage with online tribes, while Raptr and PlayFire are a hit with boomers.
The FDA approves 22 new drugs in 2016; the Philippines orders Sanofi to stop Dengvaxia ads; new spinal muscular atrophy drug to cost $375,000
The first step is to seek leadership support, she says.
The internet strongly agrees there's an artificial intelligence revolution going on, and it's come to pharma marketing.
Data scientists are a new kind of insight and analytics professional showing up in the biopharma ranks.
Gilead forms network to encourage access to hep.-C drugs; Dentsu CEO to resign following the suicide of a staffer; BI to divest animal-health products
We at MM&M found out just how much pharma marketers love a list. Here, read through the year's most-read technology stories.
Sanofi sues Novo over Tresiba marketing; the FDA issues two more untitled letters; U.S. health spending rose substantially from 1996 to 2013
Find out what stories generated the most interest among our readers.
Allergan's board endorses its social contract with patients; drugmakers that market painkillers are hiring DEA officials; the FDA approves new Biogen drug
When the vision company needed to demonstrate to parents the plight of children struggling to see, it turned to Olson 1to1 and a 360 video to tell the story.
Senate report said certain drugmakers act like hedge funds; ViiV to develop HIV prevention drug; lawmakers to replace ACA with "universal access"
Here you'll find everything you need to know from MM&M's December 2016 issue, including our policy outlook for pharma in a Republican-led White House and Congress and the exclusive pipeline report.
GSK's two-drug combo for HIV has positive Phase-III results; the FDA approves glucose system that doesn't use finger pricking; Rite Aid to sell stores
The agency has sent nine untitled and warning letters so far this year.
A recent CME course using Facebook Live generated 34,000 views and 600 comments.
Biogen names new CEO; the FDA issues two warning letters; Allergan to acquire aesthetics firm
For years pharma has said it needs to be more focused on patients, has it delivered?
The FDA drops Chantix's black-box warning; hospitals try to reduce drug spending; AstraZeneca's head of oncology to depart
MM&M conducted Q&As with Stephanie Robinson, senior account manager, The Bloc; Jessica Hill, account supervisor, Ogilvy CommonHealth; and Austin Bald, account executive, TBWA\WorldHealth.
Read what they have to say about the defining moments and challenges in their careers.
Many young staffers agree one of the biggest challenges in their careers has been learning the delicate balance of when to speak up and when to listen.
We are looking for young professionals who are determined to develop their careers in healthcare advertising and marketing.
Allergan to settle allegations relating to speakers bureaus; Mylan launches generic version of the EpiPen; 20 states sue six drugmakers accused of price-fixing
The connection to Pristiq is not overt in the app's user interface, though Moodivator is featured on Pristiq's website.
Drugmakers promote new type of opioid with unproven results; Heritage execs charged for price-fixing generics; Pershing sells more Valeant shares
Regulators said the ads distract viewers from superimposed safety information.
The previous deadline was January 9.
Obama signs 21st Century Cures Act into law; the FDA approved 19 new drugs in 2016; Sanofi in talks to acquire Actelion
Eli Lilly partnered with Express Scripts to improve adherence for diabetes patients with high-deductible health plans.
Lilly to offer discounts for insulin products; Trump reportedly considering Scott Gottlieb to lead FDA; three execs depart Valeant
Bob Chandler retired from his role as cofounder and principal of Chandler Chicco Companies and president of InVentiv Health Communications in 2014.
TV actress Jamie Lynn Sigler shares her experience using the multiple-sclerosis drug in the branded campaign.
Generic Tamiflu estimated to generate $500 million in savings this year; ADA expected to launch new diabetes treatment guidelines; Alexion CEO resigns
It is also seeking industry input for a new category of honoree, the Top 10 Innovation Catalysts.
On the heels of Keytruda's approval in first-line lung cancer, the drugmaker kicked off an unbranded campaign raising awareness about biomarkers.
BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA
The risk of fraud is also very real, especially in an industry that already faces privacy and compliance challenges, one expert says.
A California lawmaker reintroduces drug-pricing bill; France, Poland, Spain, and Sweden lobby to host EMA; drug stocks fall after Trump's comments
Pharma can reach physicians within the EHR, but they must send the right message at the right time, she said at an MM&M event.
Wilson will succeed founder and CEO John Seng.
This is W2O Group's third acquisition since a private-equity firm took an investment in May.
The bill now heads to President Obama's desk. He is expected to sign the sweeping piece of legislation.
Trump puts pharma on notice over drug prices; Mylan lays off nearly 10% of its workforce; Pfizer slapped with U.K. antitrust fine
The drugmaker is using Propeller Health's sensor technology to find new ways to improve adherence in clinical studies.
Boehringer Ingelheim and Eli Lilly have to position their third-in-class diabetes medication Jardiance as a heart drug.
Prices of Viagra and Cialis triple since 2010; AstraZeneca's Tagrisso slows lung-cancer progression compared to chemo; Novo Nordisk to limit price increases
The Roche veteran says that people who work in digital health need to touch others in a meaningful way.
The agency is owned by High Road Capital Partners. Sophy Regelous, the company's chief operating officer, will now lead the agency.
The FDA approves new indication for Jardiance; Novartis' CAR-T therapy eliminates leukemia in 82% of patients in trial; doctors report risks associated with immunotherapy
However, the rate of drug spending slowed compared to last year, according to an analysis by the CMS.
The search-engine giant says that one in 20 online searches are related to healthcare, and more users are using mobile to consume media.
Regeneron and Pfizer CEOs argue about the industry's reputation; Mylan CEO defends the EpiPen; Pfizer and IBM to partner on cancer immunotherapies
Heather Bresch's appearance at industry summit came after she declined to attend a congressional hearing scheduled for the same day.
Valeant doesn't plan to offload Salix; heart docs back Califf as commish; Saunders says pricing issues aren't affected by election
The bill includes two provisions that would address drugmakers' calls for clarity on sharing off-label information with payers and regulators.
How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy
Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey
Companies such as Eli Lilly and Medtronic have launched branded apps for their products, but experts say they don't make sense for all medicines.
The bill includes provisions to investigate the usefulness of off-label information but will no longer exempt drugmakers from reporting CME payments.
The drugmaker still views Instagram as a viable marketing platform, however.
Trump selects Price as head of HHS; Warren criticizes 21st Century Cures; GSK CEO says companies will have to get used to making less money
The drugmaker's new EVP of worldwide commercial operations also talks about tackling medication access, product launches, and starting a commercial team from scratch.
J&J in talks to buy Actelion; Novo Nordisk pulls ads on Breitbart News; Takeda to market Ninlaro in Europe
Here's a look at 100 experimental therapies in late-stage clinical trials.
A new survey found that U.S. pharma marketers prefer using social media and mobile apps to reach healthcare providers.
Lilly's experimental Alzheimer's drug fails in another trial; two more patients die during trial for Juno's CAR-T therapy; NEJM launches platform in China
The FDA approved Sanofi's Soliqua and Novo Nordisk's Xultophy on Tuesday.
More barriers separate doctors and patients than ever before, from rising costs and time constraints to electronic health records and smartphones.
Most physicians said EHRs have negatively impacted their communication with a patients.
Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials
The drugstore chain added drug effectiveness reviews and other information from PatientsLikeMe to its website.
Novartis to delay clinical trials of contact lens for diabetes patients; the ADA calls for hearings on insulin pricing; Vice launches healthcare channel
- Five things for pharma marketers to know: Thursday, January 12, 2017
- Infographic: Can pharma give doctors what they want?
- Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?
- Klick Health's Elliot Langerman on the Power of Persuasion
- Physicians group urges metformin rather than new drugs
- Five things for pharma marketers to know: Tuesday, January 17, 2017
- Trump administration raises questions for rare-disease drugmakers
- If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold
- Five things for pharma marketers to know: Friday, January 13, 2017
- Klick Health's Elliot Langerman on the Power of Persuasion